Calling for an exponential escalation scheme in vaccine development for COVID-19

PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines. METHODS: Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. RESULTS: Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an inte...

Descripción completa

Detalles Bibliográficos
Autor principal: Wehling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297510/
https://www.ncbi.nlm.nih.gov/pubmed/32548679
http://dx.doi.org/10.1007/s00228-020-02933-w
_version_ 1783547021288800256
author Wehling, Martin
author_facet Wehling, Martin
author_sort Wehling, Martin
collection PubMed
description PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines. METHODS: Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. RESULTS: Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. CONCLUSION: A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.
format Online
Article
Text
id pubmed-7297510
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72975102020-06-17 Calling for an exponential escalation scheme in vaccine development for COVID-19 Wehling, Martin Eur J Clin Pharmacol Point of View PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines. METHODS: Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. RESULTS: Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. CONCLUSION: A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes. Springer Berlin Heidelberg 2020-06-16 2020 /pmc/articles/PMC7297510/ /pubmed/32548679 http://dx.doi.org/10.1007/s00228-020-02933-w Text en © The Author(s) 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Point of View
Wehling, Martin
Calling for an exponential escalation scheme in vaccine development for COVID-19
title Calling for an exponential escalation scheme in vaccine development for COVID-19
title_full Calling for an exponential escalation scheme in vaccine development for COVID-19
title_fullStr Calling for an exponential escalation scheme in vaccine development for COVID-19
title_full_unstemmed Calling for an exponential escalation scheme in vaccine development for COVID-19
title_short Calling for an exponential escalation scheme in vaccine development for COVID-19
title_sort calling for an exponential escalation scheme in vaccine development for covid-19
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297510/
https://www.ncbi.nlm.nih.gov/pubmed/32548679
http://dx.doi.org/10.1007/s00228-020-02933-w
work_keys_str_mv AT wehlingmartin callingforanexponentialescalationschemeinvaccinedevelopmentforcovid19

Ejemplares similares